Table 1

Clinical characteristics of study subjects

CKD

Non-CKD

Total

(n = 546)

(n = 2,777)

(n = 3,323)


Age (years)

60.6 ± 7.2

55.9 ± 8.7

56.7 ± 8.6

Male

252(46.2%)

1,364(49.1%)

1,616(48.6%)

Body mass index

23.5 ± 3.1

23.4 ± 3.3

23.4 ± 3.3

Hypertension

245(44.9%)

1,050(37.8%)

1,295(39.0%)

Systolic blood pressure (mm Hg)

130.5 ± 19.8

128.1 ± 19.3

128.5 ± 19.4

Diastolic blood pressure (mm Hg)

79.1 ± 12.4

78.6 ± 11.9

78.7 ± 12.0

Anti-hypertensive medication

146(26.7%)

503(18.1%)

649(19.5%)

Diabetes mellitus

54(9.9%)

220(7.9%)

274(8.2%)

Fasting plasma glucose (mmol/l)

5.49 ± 1.23

5.55 ± 1.17

5.54 ± 1.17

HbA1c (%)

5.22 ± 0.69

5.22 ± 0.66

5.22 ± 0.67

Glucose-lowering medication

28(5.1%)

117(4.2%)

145(4.4%)

Cardiovascular diseases

34(6.2%)

80(2.9%)

114(3.4%)

Total cholesterol (mmol/l)

5.66 ± 0.88

5.46 ± 0.83

5.50 ± 0.88

HDL cholesterol (mmol/l)

1.60 ± 0.41

1.64 ± 0.42

1.63 ± 0.42

Lipid-lowering medication

68(12.5%)

233(8.4%)

301(9.1%)

Uric acid (μmol/l)

333 ± 89

303 ± 77

309 ± 83

Current smokers

68(12.5%)

495(17.8%)

563(16.9%)


Results are expressed as mean ± SD or number (%). CKD = chronic kidney disease. CKD is defined by eGFR < 60 ml/min/1.73 m2. Hypertension = blood pressure ≥ 140/90 mmHg or under anti-hypertensive medication. Diabetes mellitus = fasting blood glucose ≥ 126 mg/dl, HbA1c ≥ 6.5% or under glucose-lowering medication.

Okada et al. BMC Nephrology 2012 13:2   doi:10.1186/1471-2369-13-2

Open Data